<DOC>
	<DOCNO>NCT02513550</DOCNO>
	<brief_summary>The main purpose study evaluate efficacy ixekizumab dose regimen participant plaque psoriasis .</brief_summary>
	<brief_title>A Study Comparing Different Dosing Regimens Ixekizumab ( LY2439821 ) Participants With Moderate Severe Plaque Psoriasis</brief_title>
	<detailed_description>The purpose study evaluate safety efficacy ixekizumab dosing regimen . There 3 study period : Screening Period , Blinded Treatment Dosing Period , Post-Treatment Follow-Up .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Present chronic plaque psoriasis least 6 month prior enrollment At least 10 % BSA psoriasis screen enrollment sPGA score least 3 PASI score least 12 screen enrollment Candidates phototherapy and/or systemic therapy Participant must agree use reliable method birth control study ; woman must continue use birth control least 12 week stop treatment Predominant pattern pustular , erythrodermic , guttate form psoriasis History druginduced psoriasis Can avoid excessive sun exposure use tan booth least 4 week prior enrollment study Received systemic nonbiologic psoriasis therapy phototherapy within previous 4 week ; topical psoriasis treatment within previous 2 week prior enrollment Concurrent recent use biologic agent Have participate study ixekizumab Received live vaccination within 12 week prior enrollment Serious disorder illness psoriasis Ongoing serious infection within last 12 week evidence tuberculosis Major surgery within 8 week baseline , require surgery study Breastfeeding nursing ( lactate ) woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>